189 related articles for article (PubMed ID: 25335122)
1. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
Serrano E; Wahn HU; Didier A; Bachert C
Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.
Devillier P; Dreyfus JF; Demoly P; Calderón MA
BMC Med; 2014 May; 12():71. PubMed ID: 24885894
[TBL] [Abstract][Full Text] [Related]
3. Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis.
Blaiss MS; Durham SR; Bernstein D; Stranzl T; Lindholm M; Nolte H; Andersen KF; Roberts G
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1520-1529.e5. PubMed ID: 38307205
[TBL] [Abstract][Full Text] [Related]
4. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
Durham SR; Emminger W; Kapp A; de Monchy JG; Rak S; Scadding GK; Wurtzen PA; Andersen JS; Tholstrup B; Riis B; Dahl R
J Allergy Clin Immunol; 2012 Mar; 129(3):717-725.e5. PubMed ID: 22285278
[TBL] [Abstract][Full Text] [Related]
5. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score.
Didier A; Malling HJ; Worm M; Horak F; Sussman GL
Clin Transl Allergy; 2015; 5():12. PubMed ID: 26097680
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
Nelson HS; Bernstein DI; Biedermann T; Nolte H
Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
[No Abstract] [Full Text] [Related]
7. Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study.
Horn A; Zeuner H; Wolf H; Schnitker J; Wüstenberg E;
Clin Drug Investig; 2016 Jun; 36(6):453-62. PubMed ID: 26979593
[TBL] [Abstract][Full Text] [Related]
8. Development of a sublingual allergy vaccine for grass pollinosis.
Frati F; Scurati S; Puccinelli P; David M; Hilaire C; Capecce M; Marcucci F; Incorvaia C
Drug Des Devel Ther; 2010 Jul; 4():99-105. PubMed ID: 20689696
[TBL] [Abstract][Full Text] [Related]
9. Allergen injection immunotherapy for seasonal allergic rhinitis.
Calderon MA; Alves B; Jacobson M; Hurwitz B; Sheikh A; Durham S
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001936. PubMed ID: 17253469
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of sublingual versus vestibular allergy immunotherapy tablet administration: A randomized pilot study.
Simard ML; Novak N; Drolet JP; Joly MC; Nolte H; Wuestenberg E; Gagnon R
Clin Exp Allergy; 2024 Feb; 54(2):120-129. PubMed ID: 37990117
[TBL] [Abstract][Full Text] [Related]
11. Tablet allergen immunotherapy: the anaphylaxis issue.
Ciprandi G; Naso M; Tosca MA
Allergol Immunopathol (Madr); 2024; 52(3):73-77. PubMed ID: 38721958
[TBL] [Abstract][Full Text] [Related]
12. Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax®.
Calderón M; Brandt T
Ther Clin Risk Manag; 2008 Dec; 4(6):1255-60. PubMed ID: 19337432
[TBL] [Abstract][Full Text] [Related]
13. Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study.
Radcliffe MJ; Lewith GT; Turner RG; Prescott P; Church MK; Holgate ST
BMJ; 2003 Aug; 327(7409):251-4. PubMed ID: 12896934
[TBL] [Abstract][Full Text] [Related]
14. Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis.
Scaparrotta A; Attanasi M; Petrosino MI; Di Filippo P; Di Pillo S; Chiarelli F
Drug Des Devel Ther; 2015; 9():5897-909. PubMed ID: 26604688
[TBL] [Abstract][Full Text] [Related]
15. Specific immunotherapy in grass pollen allergy.
Mailhol C; Didier A
Hum Vaccin Immunother; 2012 Oct; 8(10):1544-7. PubMed ID: 23095875
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain.
Antolín-Amerigo D; Tabar IA; Del Mar Fernández-Nieto M; Callejo-Melgosa AM; Muñoz-Bellido FJ; Martínez-Alonso JC; Méndez-Alcalde JD; Reche M; Rodríguez-Trabado A; Rosado-Ingelmo A; Alonso-Gómez A; Blanco-González R; Alvarez-Fernandez JA; Botella I; Valls A; Cimarra M; Blanco C
Drugs Context; 2017; 6():212309. PubMed ID: 29225657
[TBL] [Abstract][Full Text] [Related]
17. Carrageenan-Containing Nasal Spray Alleviates Allergic Symptoms in Participants with Grass Pollen Allergy: A Randomized, Controlled, Crossover Clinical Trial.
Unger-Manhart N; Morokutti-Kurz M; Zieglmayer PU; Lemell P; Savli M; Zieglmayer R; Prieschl-Grassauer E
Int J Gen Med; 2024; 17():419-428. PubMed ID: 38333020
[TBL] [Abstract][Full Text] [Related]
18. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.
Köther J; Mandl A; Allekotte S; Astvatsatourov A; Chwieralski J; Liedtke JP; Pieper-Fürst U; Raskopf E; Shah-Hosseini K; Mösges R
Clin Transl Allergy; 2018; 8():28. PubMed ID: 29997888
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Japanese cedar pollen sublingual immunotherapy tablets for Japanese cypress pollinosis.
Kurokawa T; Yonekura S; Gotoh M; Okano M; Maekawa Y; Okubo K; Okamoto Y
J Allergy Clin Immunol Glob; 2023 May; 2(2):100075. PubMed ID: 37780797
[TBL] [Abstract][Full Text] [Related]
20. GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization.
Barber D; Rico P; Blanco C; Fernandez-Rivas M; Ibañez MD; Escribese MM
Hum Vaccin Immunother; 2019; 15(12):2887-2895. PubMed ID: 31157592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
